![]() This diet is high in fish, vegetables, and nuts, and low in red meat. ![]() The main diet has been shown to be neuroprotective is the Mediterranean diet. Small clinical studies in different neurological diseases have suggested that MSCs are safe.So people who are overweight have a higher chance of developing MS and people who have MS who are overweight tend to have more active disease and a faster onset of progression. These results led to the conclusion that therapeutic use of MSCs should initially focus on individuals with multiple sclerosis and persistent inflammation. Surprisingly, these effects do not require full CNS engraftment by MSCs, but rely on the capacity of MSCs to inhibit pathogenic immune responses and release neuroprotective and pro-oligodendrogenic molecules favouring tissue repair. ![]() In experimental autoimmune encephalomyelitis, intravenous injection of MSCs ameliorates clinical course and decreases demyelination, immune infiltrates, and axonal loss. Evidence from preclinical studies suggested that mesenchymal stem cells (MSCs), a subset of adult progenitor cells, are an effective therapy in preclinical animal models of neurological diseases such as experimental autoimmune encephalomyelitis, a model for multiple sclerosis, and stroke. With these multiple capabilities, MSCs have been highly regarded as an effective transplantable cell source for regenerative medicine. Mesenchymal stromal cells (MSCs) are multi-potent cells that have the capability of differentiating into adipogenic, osteogenic, chondrogenic and neural cells. The rationale for use of adult stem cells as a treatment for neurological diseases such as multiple sclerosis arose from the hope that they had the capacity to foster repair of the CNS through tissue integration and differentiation into neural cells. Stem cells derived from adult source, as well as placental tissues have been successfully probed to generate tissues of the nervous system during disease conditions. Nervous system has limited regenerative potential. There is also evidence of cerebral flow insufficiency into the gray matter in MS suggesting harbinger of neurodegeneration. So during inflammatory stage, the immune system gets activated and nerves get demyelinated while during remission stage, immune attack subsides, and the resident oligiodendrocytes remyelinate. Several genetic factors including HLA-DR15, HLA-A*02 and HLA-DRB1*1501 are documented to relate with MS. Autoimmunity plays an important role in the disease outcome and body's own immune system attacks on the myelin sheath causing the damage. Primary progressive multiple sclerosis is the prototype neurodegenerative disease. About 90% of the MS is relapsing-remitting type, which is characterized by periodic attacks (relapses), followed by partial or complete recovery (remissions).It is also common to have a progressive phase of the disease and a large study showed that around 80% of cases followed by chronic progression within 20 years. Clinically MS is classified into: Primary progressive MS (PPMS), Relapsing remitting MS (RRMS), Secondary progressive MS (SPMS) and progressive relapsing MS. MS causes the removal of fatty myelin sheath from axons of the brain and spinal cord resulting reduced communication among nerve cells. The development of new therapeutic strategies is necessary to reduce the worldwide social and economic impact of neurodegenerative diseases, which produces high rates of morbidity. There is therefore a significant unmet clinical lacuna for the development of neuroprotective treatments. Although important advances in treatment to reduce relapse rate have been made in the past two decades, no treatments are available for patients with neurodegenerative MS. It is a multifocal CNS pathology constituting two distinct clinical phases corresponding to inter-related pathological processes: focal inflammation that drives activity during the relapse-remitting stage and neurodegeneration that underlies progressive disease characterized by accumulating fixed disability. Multiple sclerosis (MS) affects more than 2 million people worldwide and is the most common non-traumatic cause of disability primarily amongst American and European adults.
0 Comments
Leave a Reply. |